Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines
SARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat COVID-19. In this context, using databases such a...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/10/1129 |
| _version_ | 1827678468629856256 |
|---|---|
| author | Acharya Balkrishna Vedpriya Arya Akansha Rohela Ashwani Kumar Rachna Verma Dinesh Kumar Eugenie Nepovimova Kamil Kuca Naveen Thakur Nikesh Thakur Pankaj Kumar |
| author_facet | Acharya Balkrishna Vedpriya Arya Akansha Rohela Ashwani Kumar Rachna Verma Dinesh Kumar Eugenie Nepovimova Kamil Kuca Naveen Thakur Nikesh Thakur Pankaj Kumar |
| author_sort | Acharya Balkrishna |
| collection | DOAJ |
| description | SARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat COVID-19. In this context, using databases such as PubMed, Google Scholar, and Science Direct, we gathered information about nanotechnology’s involvement in the prevention, diagnosis and virus-like particle vaccine development. This review revealed that various nanomaterials like gold, polymeric, graphene and poly amino ester with carboxyl group coated magnetic nanoparticles have been explored for the fast detection of SARS-CoV-2. Personal protective equipment fabricated with nanoparticles, such as gloves, masks, clothes, surfactants, and Ag, TiO<sub>2</sub> based disinfectants played an essential role in halting COVID-19 transmission. Nanoparticles are used not only in vaccine delivery, such as lipid nanoparticles mediated transport of mRNA-based Pfizer and Moderna vaccines, but also in the development of vaccine as the virus-like particles elicit an immune response. There are now 18 virus-like particle vaccines in pre-clinical development, with one of them, developed by Novavax, reported being in phase 3 trials. Due to the probability of upcoming COVID-19 waves, and the rise of new diseases, the future relevance of virus-like particles is imperative. Furthermore, psychosocial variables linked to vaccine reluctance constitute a critical problem that must be addressed immediately to avert pandemic. |
| first_indexed | 2024-03-10T06:09:38Z |
| format | Article |
| id | doaj.art-9a20bf3f99354cef8c20c7efe2212a2c |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T06:09:38Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-9a20bf3f99354cef8c20c7efe2212a2c2023-11-22T20:15:37ZengMDPI AGVaccines2076-393X2021-10-01910112910.3390/vaccines9101129Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle VaccinesAcharya Balkrishna0Vedpriya Arya1Akansha Rohela2Ashwani Kumar3Rachna Verma4Dinesh Kumar5Eugenie Nepovimova6Kamil Kuca7Naveen Thakur8Nikesh Thakur9Pankaj Kumar10Patanjali Herbal Research Department, Patanjali Research Institute, Haridwar 249405, IndiaPatanjali Herbal Research Department, Patanjali Research Institute, Haridwar 249405, IndiaPatanjali Herbal Research Department, Patanjali Research Institute, Haridwar 249405, IndiaPatanjali Herbal Research Department, Patanjali Research Institute, Haridwar 249405, IndiaSchool of Biological and Environmental Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173229, IndiaSchool of Bioengineering and Food Technology, Shoolini University of Biotechnology and Management Sciences, Solan 173229, IndiaDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, 50003 Hradec Kralove, Czech RepublicDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, 50003 Hradec Kralove, Czech RepublicDepartment of Physics, Career Point University, Hamirpur 177001, IndiaDepartment of Physics, Career Point University, Hamirpur 177001, IndiaDepartment of Physics, Career Point University, Hamirpur 177001, IndiaSARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat COVID-19. In this context, using databases such as PubMed, Google Scholar, and Science Direct, we gathered information about nanotechnology’s involvement in the prevention, diagnosis and virus-like particle vaccine development. This review revealed that various nanomaterials like gold, polymeric, graphene and poly amino ester with carboxyl group coated magnetic nanoparticles have been explored for the fast detection of SARS-CoV-2. Personal protective equipment fabricated with nanoparticles, such as gloves, masks, clothes, surfactants, and Ag, TiO<sub>2</sub> based disinfectants played an essential role in halting COVID-19 transmission. Nanoparticles are used not only in vaccine delivery, such as lipid nanoparticles mediated transport of mRNA-based Pfizer and Moderna vaccines, but also in the development of vaccine as the virus-like particles elicit an immune response. There are now 18 virus-like particle vaccines in pre-clinical development, with one of them, developed by Novavax, reported being in phase 3 trials. Due to the probability of upcoming COVID-19 waves, and the rise of new diseases, the future relevance of virus-like particles is imperative. Furthermore, psychosocial variables linked to vaccine reluctance constitute a critical problem that must be addressed immediately to avert pandemic.https://www.mdpi.com/2076-393X/9/10/1129SARS-CoV-2COVID-19diagnosisvirus-like particle vaccinesprevention |
| spellingShingle | Acharya Balkrishna Vedpriya Arya Akansha Rohela Ashwani Kumar Rachna Verma Dinesh Kumar Eugenie Nepovimova Kamil Kuca Naveen Thakur Nikesh Thakur Pankaj Kumar Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines Vaccines SARS-CoV-2 COVID-19 diagnosis virus-like particle vaccines prevention |
| title | Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines |
| title_full | Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines |
| title_fullStr | Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines |
| title_full_unstemmed | Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines |
| title_short | Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines |
| title_sort | nanotechnology interventions in the management of covid 19 prevention diagnosis and virus like particle vaccines |
| topic | SARS-CoV-2 COVID-19 diagnosis virus-like particle vaccines prevention |
| url | https://www.mdpi.com/2076-393X/9/10/1129 |
| work_keys_str_mv | AT acharyabalkrishna nanotechnologyinterventionsinthemanagementofcovid19preventiondiagnosisandviruslikeparticlevaccines AT vedpriyaarya nanotechnologyinterventionsinthemanagementofcovid19preventiondiagnosisandviruslikeparticlevaccines AT akansharohela nanotechnologyinterventionsinthemanagementofcovid19preventiondiagnosisandviruslikeparticlevaccines AT ashwanikumar nanotechnologyinterventionsinthemanagementofcovid19preventiondiagnosisandviruslikeparticlevaccines AT rachnaverma nanotechnologyinterventionsinthemanagementofcovid19preventiondiagnosisandviruslikeparticlevaccines AT dineshkumar nanotechnologyinterventionsinthemanagementofcovid19preventiondiagnosisandviruslikeparticlevaccines AT eugenienepovimova nanotechnologyinterventionsinthemanagementofcovid19preventiondiagnosisandviruslikeparticlevaccines AT kamilkuca nanotechnologyinterventionsinthemanagementofcovid19preventiondiagnosisandviruslikeparticlevaccines AT naveenthakur nanotechnologyinterventionsinthemanagementofcovid19preventiondiagnosisandviruslikeparticlevaccines AT nikeshthakur nanotechnologyinterventionsinthemanagementofcovid19preventiondiagnosisandviruslikeparticlevaccines AT pankajkumar nanotechnologyinterventionsinthemanagementofcovid19preventiondiagnosisandviruslikeparticlevaccines |